ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Informatics

BenevolentAI raises $115 million

by Ryan Cross
April 29, 2018 | APPEARED IN VOLUME 96, ISSUE 18

 

The London-based start-up BenevolentAI has raised an additional $115 million to use artificial intelligence to guide drug discovery and development. The fundraising brings the company’s total funding to more than $200 million and its valuation to some $2 billion. The company’s drug programs include Parkinson’s disease and glioblastoma. BenevolentAI plans to nearly double its size, to 300 employees, within a year. The new funds came from existing investors and new, unnamed U.S. investors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment